FDA warning: Ozempic, other weight-loss drugs can cause vision loss
The Food and Drug Administration on Monday said popular GLP-1 weight-loss medications such as Ozempic, Wegovy and others must put a warning about greater risks for permanent vision loss on their packaging.
The Food and Drug Administration has mandated that popular GLP-1 weight-loss medications, including Ozempic and Wegovy, must now feature a warning on their packaging. This warning highlights an increased risk of permanent vision loss associated with these drugs. The directive was issued on Monday.
- FDA mandates warning for GLP-1 weight-loss medications.
- Drugs like Ozempic and Wegovy must include a warning.
- The warning concerns a greater risk of permanent vision loss.
- The FDA issued this directive on Monday.
Write a comment